

1 **Brain Ischemia in Alzheimer’s disease counteracts the Disruption of the Blood**
2 **Brain Barrier: A Hypothesis Investigated with a Lumped Parameter Model.**

3 Grant A Bateman*^{1,2}. Alexander R Bateman³

4

5

6

7 1. Department of Medical Imaging, John Hunter Hospital, Newcastle, NSW, Australia

8 2. Newcastle University Faculty of Health, Callaghan Campus, Newcastle, NSW,

9 Australia

10 3. School of Mechanical Engineering, University of New South Wales, Sydney, NSW,

11 Australia

12

13

14 Running title: Ischemia and BBB in AD

15

16

17

18

19

20

21

22

23

24

25 Correspondence: Dr Grant Bateman

26 ORCID: <https://orcid.org/0000-0003-3095-9047>

27 Department of Medical Imaging

28 John Hunter Hospital

29 Locked Bag 1

30 Newcastle Region Mail Center

31 2310 Australia

32 Phone: 61 2 49213414

33 Fax: 61 2 49213428

34 Email: grant.bateman@health.nsw.gov.au

35 **Abstract**

36 *Background:* In normal pressure hydrocephalus (NPH) there is blood brain barrier (BBB)
37 disruption, which should increase the CSF formation rate (CSF_{fr}) and therefore the intracranial
38 pressure (ICP). However, the ICP is normal in NPH. A lumped parameter study suggested that the
39 CSF_{fr} could be reduced in this condition if the BBB disruption was moderated by a reduction in the
40 capillary transmural pressure (TMP) secondary to arteriolar constriction. In early Alzheimer's
41 disease (AD), there is BBB disruption, reduced ICP and global ischemia. This raises the possibility
42 that the same physiology may be occurring in AD as occurs in NPH.

43 *Objective:* This hypothesis can be analyzed further using a lumped parameter hydrodynamic model
44 we have developed.

45 *Methods:* A lumped parameter model previously used to describe the hydrodynamics of NPH was
46 modified to investigate the effects of changes in CSF pressure and blood flow in patients with mild
47 cognitive impairment (MCI) and AD.

48 *Results:* The model indicates the capillary TMP is normal in MCI but decreases as AD progresses.
49 Removing CSF in AD patients during a tap test initially increases the capillary TMP. The brain in
50 AD responds to a tap test by increasing its level of ischemia and this reduces the capillary TMP.

51 *Conclusions:* A hypothesis is put forward that the BBB disruption in AD is partially mitigated by
52 the brain making itself ischemic. Modelling gives support to this hypothesis. The model can explain
53 the development of ischemic neuronal loss and amyloid accumulation secondary to glymphatic flow
54 disruption as AD progresses.

55 *Key words:* Alzheimer's disease; blood brain barrier; cerebral blood flow; CSF formation rate;
56 glymphatic; ischemia

57

58

59 **Introduction**

60 Alzheimer's disease (AD) is the commonest cause of dementia in the elderly population. It
61 is characterized by brain atrophy and gradual cognitive decline, which correlates with a loss of
62 neuronal synapses and cell death.¹ The exact pathophysiology of this disease remains difficult to
63 discern. There is evidence to suggest that blood brain barrier (BBB) disruption occurs early in AD.
64 In a study of mild cognitive impairment (MCI) due to AD and early AD using an MRI gadolinium
65 contrast protocol, there was global leakage of contrast, with a higher volume fraction of leaking
66 brain tissue in the cortex, deep grey matter and normal appearing white matter correlating with
67 disease stage.² In both MCI and early AD, the mini mental state examination (MMSE) decreases
68 significantly with increasing leakage of the BBB in the grey matter.² The BBB protects the brain
69 from blood derived toxic molecules, cells and microorganisms and also regulates the transport of
70 nutrients and the clearance of metabolic end products and endogenous neurotoxins.³ The fact that
71 the BBB breakdown occurs early in individuals with MCI and AD,⁴ even preceding hippocampal
72 degeneration,⁵ suggests it may be an initiating event. In acute brain insults such as cerebritis, there
73 is the production of vasogenic edema.⁶ Vasogenic edema is due to BBB disruption and results in
74 extravasation of fluid and intravascular proteins such as albumin into the cerebral parenchyma.⁶
75 Excessive accumulation of this fluid evokes an increase in the intracranial pressure (ICP) because
76 there is continuity between the interstitial and the subarachnoid spaces.⁶ Therefore, BBB breakdown
77 in AD would be expected to increase the ICP. However, the opposite occurs, with a reduction in the
78 ICP in AD over time. In a large study measuring the ICP in MCI and AD, there was a significant
79 linear correlation between the reduction in the MMSE and a reduced ICP across the whole cohort.⁷
80 Thus, the progressive reduction in the ICP, despite the progressive opening of the BBB in AD,
81 appears to be an enigma.

82 There is a high correlation between the pathology of AD and normal pressure hydrocephalus
83 (NPH) found at brain biopsy performed whilst inserting a shunt to treat NPH.⁸ The syndrome of
84 NPH was first described by Adams et al. almost 60 years ago, in patients with a classical clinical
85 triad of ataxia, incontinence and dementia.⁹ These patients were found to have dilated ventricles but
86 a normal cerebrospinal fluid (CSF) pressure.⁹ The ICP is normal in NPH despite there being a
87 significant disruption of the BBB.¹⁰ As discussed, this suggests an anomaly in NPH
88 pathophysiology similar to AD. Thus, there may be some pathophysiological overlap between NPH
89 and AD. A lumped parameter hydrodynamic study of the brain in NPH performed by the current
90 authors was performed to investigate this anomaly. This study suggested that the expected increased
91 ICP in NPH could be moderated if the capillary pressure were reduced by arterial constriction
92 leading to cerebral ischemia.¹¹ Interestingly, a reduced cerebral blood flow (CBF) is also found to
93 be a component of AD. A study by one of the current authors, showed the mean arterial pressure to
94 be the same in a cohort of AD patients as compared to aged match controls. Using 2D phase
95 contrast MR flow quantification, the total arterial inflow in the AD patients was measured to be
96 18% lower than the controls. Dividing the total blood flow by the mean arterial pressure suggested
97 the vascular resistance in AD was increased by 23% ($p=0.02$) compared to the controls.¹² This
98 indicated a probable significant arterial dysfunction in AD, provided the capillary or venous
99 pressure were not affected. In a large study, decreased global CBF was associated with worse
100 cognitive performance in AD and impairment in all cognitive domains.¹³ There is a linear reduction
101 in both CBF and the MMSE in AD patients over time, with a strong relationship between the
102 decrease in global CBF and cognition.¹⁴ The similarities between the breakdown in the BBB, the
103 reduced or moderated ICP and evidence of cerebral ischemia between NPH and AD is striking. This
104 suggests to us a possible hypothesis i.e., the brain is inducing ischemia within its parenchyma in AD
105 as a way of moderating the effects of the BBB disruption in a way similar to NPH. This hypothesis

106 could be investigated further using the lumped parameter model we have previously developed.
107 Therefore, the purpose of the current study is to extend the original lumped parameter model, to
108 incorporate the ICP and ischemia in AD to test the hypothesis that the brain is reducing its blood
109 flow as a way of moderating the ICP and the effects of the disruption of the BBB.

110 **Materials and Methods**

111 A detailed description of the model can be obtained from the original paper.¹¹ A brief
112 description is given to outline the methods used.

113 *Equations*

114 Davson's equation relates the intracranial pressure to the CSF formation rate, the CSF
115 outflow resistance and the venous sinus pressure,¹⁵

$$116 \quad ICP = CSF_{fr} \times R_{out} + P_{sss} \quad (1)$$

117 where ICP is the intracranial pressure, CSF_{fr} is the CSF formation rate, R_{out} is the CSF outflow
118 resistance and P_{sss} is the pressure in the superior sagittal sinus. Next Ohms law for hydraulic circuits
119 is required:

$$120 \quad \Delta P = Q \times R \quad (2)$$

121 where ΔP is the pressure drop across a vascular segment, Q is the flow rate through the segment and
122 R is the resistance. Resistances in series are additive so the following can be derived:

$$123 \quad R_{art} + R_{cap} + R_{ven} + R_{cuf} = R_{tot} \quad (3)$$

124 where R_{art} is the arterial segment resistance, R_{cap} is the resistance in the capillaries, R_{ven} is the
125 venous resistance, R_{cuf} is the resistance of the venous outflow cuff and R_{tot} is the total resistance for
126 the entire vascular system. Poiseuille's equation calculates the pressure drop across each of these
127 segments:

$$128 \quad \Delta P = \frac{8\mu LQ}{\pi r^4} \quad (4)$$

129 where ΔP is the pressure drop, μ is the viscosity, L is the vessel length, Q is the fluid flow rate, π is
130 the circle proportionality constant and r is the radius. Substituting equation (2) into (4) and
131 eliminating Q from both sides gives an equation for the resistance in each segment:

$$132 \quad R = \frac{8\mu L}{\pi r^4} \quad (5)$$

133 In this modeling study the viscosity, the length of each vessel segment, and π are constants, so it can
134 be shown that a change in resistance for any segment depends only on a change in the vessel radius
135 i.e.

$$136 \quad \Delta R = \Delta r^{-4} \quad (6)$$

137 The volume of a vessel is given by the equation for a cylinder i.e.

$$138 \quad V = L\pi r^2 \quad (7)$$

139 where V is the volume, L is the vessel length and r is the radius of the vessel. Given L and π are
140 constants for any given segment, the change in volume is dependent on the change in radius i.e.

$$141 \quad \Delta V = \Delta r^2 \quad (8)$$

142 Substituting equation (8) into equation (6) gives

$$143 \quad \Delta R = \Delta V^{-2} \quad (9)$$

144 The next required equation relates the transmural pressure across a vessel to the vessel cross-
145 sectional area:¹⁶

$$146 \quad P_{tm} = \frac{4Eh}{3R_o} \left(1 - \sqrt{\frac{A_o}{A}}\right) \quad (10)$$

147 where P_{tm} is the transmural pressure across the vessel wall, E is the circumferential Young's
148 modulus of the vessel wall, h is the wall thickness, R_o is the radius in the stress free state, A_o is the
149 area in the stress free state and A is the area following the applied transmural pressure. This
150 equation was previously used to show that the volume of the venous outflow varies with the
151 transmural pressure giving the equation:¹¹

152
$$\Delta TMP_{ven} = -0.033\Delta V_{ven}^2 + 7.49 \times \Delta V_{ven} - 3.44 \quad (11)$$

153 where ΔTMP_{ven} is the normalized increase in venous transmural pressure and ΔV_{ven} is the change in
154 venous volume. The pressure within the venous outflow sinuses depends on the central venous
155 pressure and the pressure drop across the venous sinuses to the level of the jugular bulbs. The
156 normal central venous pressure is 5 ± 0.7 mmHg.¹⁷ Although the pressure drop across the venous
157 outflow has been found to have a quadratic relationship with the CBF,¹⁸ the relationship of the
158 portion of the graph between a normal flow rate and zero flow is almost linear. Thus, the venous
159 sinus pressure can be found using the simplified equation:

160
$$P_{SSS} = 3.3 \times CBF + 5 \quad (12)$$

161 Where P_{SSS} is the pressure in mmHg and CBF is the blood flow in L/min.

162 *Model input parameters*

163 The input parameters are unchanged from the previous study¹¹ and will only be briefly
164 described as the details can be obtained from the original study. The brain size is 1500g. A CBF is
165 50 ml/100g/min.¹⁹ The cerebral blood arterial inflow is 750 ml/min. The arterial inflow pressure is
166 100 mmHg.²⁰ The precapillary bed pressure is 32 mmHg.²¹ The end capillary pressure is 15
167 mmHg.²² The CSF pressure is 11.5 mmHg²³ and the pressure gradient from the CSF to the superior
168 sinus lumen is 4 mmHg,²⁴ giving a sinus pressure of 7.5 mmHg.²⁵ The transmural pressure of the
169 subarachnoid cortical veins in primates is 2.5 mmHg.²⁶ The pre-venous outflow cuff pressure is 14
170 mmHg by addition.

171 The total cerebral blood volume (CBV) is 51 ml.¹¹ The arterial component of the CBV is
172 25% of the total²⁷ or 12.8 ml. The capillaries make up 53% of the remaining volume,²⁸ giving a
173 total capillary blood volume of 20.3 ml and a total venous blood volume of 17.9 ml. The normal
174 CSF formation rate is 0.40 ml/min.²⁹

175

176 *Vessel responses to transmural pressure variations*

177 The variations in the arterial resistance and volume in this model depend entirely on the
178 arterial muscle tone and not the vessel transmural pressure. As the arterial pressure is always much
179 higher than the ICP, the arterial transmural pressure will have no effect on the outcome of the
180 current modelling study.

181 The capillary bed vessels do not actively alter their diameter,³⁰ indicating they react purely
182 to their transmural pressure. In a rat model, extreme hyperventilation decreased the PCO₂ from 40
183 to 21.6 mmHg without affecting PO₂ and the capillary size was not significantly different to the
184 controls despite the expected arteriolar constriction.³¹ However, in the opposite case, in rats made
185 extremely hypercapnic secondary to hypoventilation, the PCO₂ increased to 95.6 mmHg but PO₂
186 was normal, with the capillary diameter increasing by 20%, consistent with a 44% increase in
187 volume compared to known control values.³¹ Thus, a moderate reduction in capillary trans mural
188 pressure (TMP) does not change the capillary size but a maximal increase in TMP increases their
189 volume by 44%. To simplify the current study, it is assumed the volume of the capillaries vary
190 between normal and maximally dilated as a linear function of their transmural pressure. A previous
191 study indicated an increase in capillary TMP from 12 to 37.9 mmHg would increase the capillary
192 volume by 44% or a 1.7% increase in volume for each 1 mmHg pressure rise. Below a TMP of 12
193 mmHg, the volume is unchanged at 20.3 ml and above a TMP of 37.9, the elastic limit is reached
194 and the volume is set to 29.2 ml.

195 Similar to the capillaries, the veins alter their size purely depending on their transmural
196 pressures. In a previous modelling study,¹¹ the function for the outflow vein dilatation was found to
197 be summarized by equation (11).

198 At the distal end of the cortical veins, as they join the sinus wall, the outflow cuff segment
199 resides. The collapse of this segment occurs physiologically and is passively modulated by the

200 transmural pressure between the ICP and the sinus pressure, which is usually negative.³² The
201 segment is very short, and as it is mostly under a state of collapse with physiological ICPs, the
202 change in volume from this segment will be ignored in this model. This is despite acknowledging
203 that the cuff is dilated in the tap test model. However, its resistance will be taken into consideration.
204 In the previous study, four differing cuff transmural pressures resulted in 4 differing resistances.¹¹
205 When these points were plotted, a straight line with R^2 of 0.998 resulted, suggesting the cuff
206 resistance varies as a linear function of the cuff TMP. Thus, giving equation 13:

$$207 \quad R_{cuf} = -2.71 \times TMP_{cuf} + 0.008 \quad (13)$$

208 where R_{cuf} is the cuff resistance and TMP_{cuf} is the cuff transmural pressure.


209 The sagittal sinus pressure will vary with the blood flow using equation (12).

210 **Results**

211 *Varying the Blood flow and ICP in AD*

212 The original study findings in NPH suggested the brain elected to be ischemic, most likely
213 to limit the capillary TMP and the CSF formation rate (CSF_{fr}).¹¹ We undertook an initial modelling
214 study to see how the changes in CBF and ICP, known to occur in MCI and AD, would alter the
215 capillary TMP to further study this effect. These initial modelling findings are summarized in
216 Figure 1. The five vascular segments modelled are shown in fig 1a, each segment has a differing
217 shade of grey. The segments from right to left are the arterial, the capillaries, the veins, outflow cuff
218 and the sinus. The pressures obtained from the literature have been appended to the beginning and
219 end of each vascular segment within the vessels in fig 1a. Given the arterial inflow volume passes
220 through each segment sequentially, the resistance of each segment can be calculated using equation
221 (2). These resistances are appended below the vessels in fig 1. The normal cerebral blood volume
222 (CBV) values for each segment and the total CBV has been obtained from the literature and are
223 shown below the resistances. The numbers above the vessel represent the transmural pressure

224 gradients between the pressure at the beginning and end of each capacitance vessel segment and the
225 ICP, and are obtained by subtraction. The extra figure above the capillary (in grey) is the mean
226 TMP obtained by averaging the TMP before and after the capillaries. Placing the ICP, venous
227 pressure and normal CSF_{fr} in equation 1 gives a normal R_{out} of 10 mmHg/ml/min. Figures 1b-e
228 represent the effects of the differing alterations in CBF by varying the inflow resistance and ICP. In
229 these figures, the darker grey segments represent the areas of increased resistance compared to the
230 normal findings and the lighter grey represent reduced resistance.



232 *Results of modelling changes to blood flow in AD*

233 Fig. 1a depicts the normal findings. The segments from right to left are the arterial, capillary, veins, outflow cuff and the
234 venous sinus. The vascular pressures are shown within the vessels. The numbers above the vessel are the transmural
235 pressures at each site. The resistances and volumes for each segment are shown below the vessel. Note. ICP;

236 intracranial pressure, mm; millimeters, mmHg; mmHg, millimeters of mercury, ml; millimeters.

237 Fig. 1b shows the findings in MCI. The dark grey area indicating an increase in resistance in the arteries and the lighter
238 grey decreased resistance in the veins compared to normal.

239 Fig. 1c shows the findings in mild AD. The dark grey area shows a further increase in arterial resistance and some
240 increase in venous resistance with the lighter area a reduction in cuff resistance.

241 Fig. 1d shows the findings in moderate AD. These changes are essentially more pronounced than in mild AD.

242 Fig. 1e shows the findings in severe AD. These changes have further progressed compared to earlier.

243 Figure 1a has been reproduced from¹¹ under a CC BY 4.0 commons licence

244 In figure 1b, the findings in MCI have been modelled. The arterial inflow is unchanged as

245 per the literature. The ICP is reduced to 10.7 mmHg as per the literature. These pressure changes

246 reduced the gradient pressure across the venous cuff and the resistance of this segment was reduced

247 very slightly. The reduction in ICP dilated the veins due to the change in their TMP. There were no

248 other significant changes. Placing the ICP, venous pressure and a normal CSF outflow resistance of

249 10 mmHg/ml/min into equation 1 suggests the CSF_{fr} is reduced in MCI to 0.32 ml/min, down from

250 0.4 ml/min.

251 Figure 1c models the findings in mild AD. The ICP and the CBF come from the literature.

252 The venous sinus pressure is reduced, the cuff pressure gradient is reduced and the volume of the

253 veins reduced. The effect was to reduce the capillary TMP below that for MCI. Placing the ICP,

254 venous pressure and the normal R_{out} into equation 1 gave a CSF_{fr} of 0.25 ml/min, being a further

255 reduction compared to MCI.

256 Figure 1d models moderate AD with further reductions in ICP and CBF. The effect is

257 similar to, but more pronounced than the changes in mild AD, with the capillary TMP being further

258 reduced. The calculated CSF_{fr} is also further reduced to 0.18 ml/min

259 Figure 1e models severe AD with further reductions in CBF and ICP. The capillary TMP is

260 further reduced to 7.2 mmHg and the calculated CSF_{fr} is 0.06 ml/min. Note the total CBV has


261 decreased by 10% compared to the normal figure.

262

263 *Performing a tap test in moderate AD.*

264 The effect of performing a tap test in moderate AD is modeled in figure 2. Figure 2a is the

265 baseline moderate AD findings transposed from fig 1c for easier comparison.



266

267 *Modelling of changes secondary to a tap test in AD*

268 Fig. 2a shows the moderate AD findings reproduced from 1d for ease of comparison.

269 Fig. 2b shows the immediate finding following a tap test. Note the veins dilate reducing the venous pressure and the
270 flow increases slightly but the capillary TMP has increased.

271 Fig. 2c shows the findings in a tap test 1 minute later as the CBF drops. This required an increase in the arterial
272 resistance reducing the size of the arteries. The veins are dilated by almost the same amount meaning the total CBV is
273 almost unaltered.

274 Figure 2b is the instantaneous effect of reducing the ICP by 56% as per the literature. The
275 outflow cuff resistance is abolished due to the now positive pressure gradient across it. The
276 unchanged arterial resistance allows for a minimal increase in CBF of 3.5%. There is a reduction in
277 venous pressure but the ICP has dropped faster than this, so the capillary TMP increases by 22.5%.
278 The lighter grey indicates dilatation of the veins and reduced resistance.

279 According to the literature the effect of a tap test is to induce a 10% reduction in CBF within
280 several minutes. This effect has been modelled in fig 2c. The venous resistances are unchanged as
281 they only depend on the transmural pressures which are minimally changed. A significant increase
282 in arterial resistance is required, this reduced the capillary TMP by 14.7% compared to fig 1b
283 because the precapillary pressure dropped and the venous sinus pressure dropped. The capillary
284 TMP is reduced back towards the findings in fig 1a. Note the CBV is not significantly different from
285 2a because the venous dilatation is matched by the arterial constriction.

286 **Discussion**

287 We have hypothesized that the brain makes itself ischemic to reduce the effect of the BBB
288 breakdown in AD. We wished to test this using a previously developed lumped parameter model.
289 This model was originally verified by predicting the cerebral blood volume (CBV) changes which
290 would occur at the limits of autoregulation, utilizing both an increase and decrease in perfusion
291 pressure.¹¹ The model accurately predicted the CBV changes found in the literature for both human
292 and animal experiments.¹¹ Similarly, we can check the accuracy of the current modelling in AD by
293 comparing the predicted CBV with the literature. The model predicts a 10% reduction in CBV in
294 severe AD. In a study of 16 patients with a MMSE averaging 16/30, the CBV was reduced by 11%
295 in the cortex,³³ suggesting the model is accurate enough for the current purposes.

296 *Cerebral blood flow in MCI and AD*

297 A meta-analysis suggested no obvious changes in global CBF in MCI patients compared to
298 controls.³⁴ Therefore, we have not changed the CBF in our model for MCI. At first glance, a
299 normal global CBF in MCI would appear to make our suggestion, that a reduced CBF is the earliest
300 response to an opening of the BBB, unlikely. However, the perfusion changes in MCI are varied. In
301 a recent MRI study, there was hypo-perfusion in the right middle frontal gyrus, right and left
302 temporal gyrus and right middle temporal gyrus but hyper-perfusion in the right superior medial
303 gyrus, left and right precuneus, left superior parietal lobule, right superior frontal gyrus, and right
304 cerebellum.³⁵ Thus, the high flow areas may mask the low flow areas in MCI at a global level. As
305 previously discussed, there is a linear reduction in CBF over time in AD, with a close association
306 between this reduction and the MMSE,¹⁴ suggesting the CBF reduction is closely related to the
307 stage of the disease. In studies of mild AD with a MMSE of 26/30, the global CBF is reduced by
308 between 6-10%.^{36,37} We have chosen a figure of a 10% reduction in CBF for mild AD in our model.
309 Studies of the CBF in moderate AD suggest a reduction of between 18-21%.^{12,38,39} Therefore, we
310 have chosen a 20% reduction in CBF in moderate AD. There are few studies looking at severe AD
311 and CBF. Tohgi et al. found a 25.7% reduction in the cortex and 17.8% in the white matter in
312 severe AD.³³ However, the global CBF can be reduced up to 42% in this disease.⁴⁰ Given the linear
313 response of the MMSE to the CBF, we elected to use a reduction of 30% in our model for severe
314 AD. These reductions in CBF appear to occur despite there being no significant change in the
315 arterial blood pressure.^{12,39} Therefore, we have kept the inflow pressure normal in the model.

316 This progressive reduction in CBF in AD could be secondary to atrophy or reduced
317 metabolic activity, however, published metabolic imaging suggests otherwise. Using Positron
318 Emission Tomography and ¹⁵O labelled compounds, it is possible to measure the CBF in
319 ml/100g/min, cerebral metabolic rate of oxygen (CMRO₂) per 100g of tissue, oxygen extraction
320 fraction (OEF) and CBV in ml/100g.⁴¹ CMRO₂ measures the rate of aerobic glycolysis per 100g of

321 tissue and the OEF is the fractional extraction of oxygen transferred from the capillary to the nerve
322 cells.⁴¹ The cerebral metabolic rate of glucose (CMR_{glu}) can be measured with a radio labelled
323 glucose analogue and measures anaerobic glycolysis per 100g of tissue.⁴¹

324 When there is a fall in cerebral perfusion pressure, the first compensation measure the brain
325 performs is to dilate the arterioles to decrease their resistance and maintain the CBF and $CMRO_2$,
326 this is stage 1.⁴¹ Thus, the CBV should increase in stage 1. We note that the CBV actually
327 progressively decreases in AD³³ which is an anomaly. When the arterial vasodilatation is
328 exhausted, the CBF will fall but the $CMRO_2$ will initially be maintained by increasing the oxygen
329 extraction with an increase in OEF, this is stage 2. If perfusion pressure falls further then infarction
330 becomes a possibility.⁴¹ In 10 patients with AD judged to be moderate in severity, there were
331 reductions in CBF, $CMRO_2$ and CBV, with an increase in OEF compared to controls.⁴¹ There was a
332 profound reduction in CMR_{glu} , indicating reduced anaerobic glycolysis.⁴¹ The findings were
333 described as misery perfusion. In this study the cerebrovascular reserve was assessed using 7% CO_2
334 inhalation and hyperventilation to increase and decrease the CBF respectively.⁴¹ There was no
335 difference in values between the AD patients and controls, indicating preserved cerebrovascular
336 reserve.⁴¹ Another study found similar findings with large reductions in CBV, CBF, increased OEF
337 and reduced $CMRO_2$ ³³ and a third also indicated a 9% reduction in whole brain CMR_{glu} in early
338 AD.⁴² This highlights a large discrepancy in AD. There is misery perfusion with metabolic
339 derangement which is not just due to atrophy (the reduction occurs per 100g of tissue) but the
340 arterioles are not fully dilated, as evidenced by the reduced CBV, and there is preserved
341 cerebrovascular reserve. Therefore, the inference is that arterial constriction has caused the majority
342 of the ischemia in AD and the arteries have elected not to dilate, even though they have the capacity
343 to do so. In fact, the modelling in fig 2 suggests the arterioles actively react with a further

344 constriction if the capillary TMP increases, suggesting that reducing the TMP may be a greater
345 imperative than rectifying the metabolic insult.

346 A tap test is performed in NPH patients by removing 20-30 ml of CSF at lumbar puncture.
347 It has long been known that a tap test increases the CBF in NPH in those patients who improve
348 clinically, but the CBV falls in those who do not improve clinically.⁴³ In properly auto-regulated
349 patients, increasing the cerebral perfusion pressure should not have an effect on the CBF. Even in
350 idiopathic intracranial hypertension patients and those with a recent stroke, the CBF does not
351 change with a tap test.^{44, 45} However, in one study where a tap test was performed on AD patients,
352 the ICP was reduced by 56%, but the CBF fell by 14% within one minute. The CBV was not
353 significantly changed.⁴⁴ In another study, the tap test reduced the CBF by a further 10% on top of
354 the 14% reduction in the baseline CBF in AD patients compared to controls.⁴⁶ To study this effect,
355 we reduced the ICP by 56% in fig 2b from the moderate AD baseline in fig 2a. The immediate
356 effect would be a reduction in the venous outflow resistance and a moderate increase in CBF due to
357 the improved perfusion pressure, fig 2b. However, the capillary TMP was increased by 22.5% in fig
358 2b. Following one minute, the CBF reduces, so we reduced the CBF by 10% of the normal flow rate
359 in fig 2c to model this. This brought the capillary TMP down to be much closer to the original
360 figure in fig 2a. Note the final CBV in fig 2c is only 1% larger than the baseline moderate AD
361 value, despite the venous volume increasing by 11%. This is because the arterial volume decreased
362 by 12% and this matched the venous increase. This CBV model prediction mirrors the findings of
363 Meyer et al., in which the CBF fell but the CBV was unchanged in an AD at tap test.⁴⁵ Again, this
364 suggests our modelling is probably accurate enough for our current purposes. The interpretation is
365 that the reduction in capillary TMP may be more important to the brain than the reduction in CBF
366 that this requires.

367

368 *The blood brain barrier, CSF formation rate and the ICP*

369 As already discussed, the ICP is reduced with disease progression in AD.⁷ In the study by
370 Yang et al., the mean ICP in MCI was 10.7 mmHg, the patients with severe AD had an ICP of 7.4
371 mmHg and the average across all dementia patients (representing the level for moderate dementia)
372 was 8.8 mmHg.⁷ We used these figures for our study. Given the linear relationship of the ICP with
373 dementia grade, the value for mild dementia we used was taken to be half way between MCI and
374 moderate dementia figure i.e., 9.8 mmHg.⁷

375 The intact BBB effectively excludes significant net fluid production within the brain
376 parenchyma. The normal CSF_{fr} is 0.4 ml/min.²⁹ Of this, 0.28 ml/min comes from the choroid
377 plexus, 0.072 ml/min from the brain parenchyma and 0.048 ml/min from glucose metabolism.⁴⁷
378 Therefore, the brain parenchyma produces some interstitial fluid, which becomes incorporated into
379 the CSF production, at a rate of 0.0048 ml/100g/min. This compares to the remainder of the body
380 where interstitial fluid production contributes to the lymph fluid. For the skin, the production rate is
381 0.24 ml/100g/min, for muscle it is 0.021 ml/100g/min⁴⁸ and the liver is approximately 0.05
382 ml/100g/min⁴⁹ or 2-3 orders of magnitude greater than fluid production within the brain. The fluid
383 production can significantly increase in the brain parenchyma if there is opening of the BBB.
384 Increased arterial pressure above the autoregulation cut-off gives cerebral hyper-perfusion,
385 increased pressure within the capillaries and venules, disruption of the BBB, edema and a raised
386 ICP.³⁰ How much can a chronic disruption of the BBB increase the interstitial fluid production? In
387 NPH there is BBB breakdown.^{10, 50} There is also a 14% reduction in the CBF in the cortex and a
388 40% reduction in the white matter.⁵¹ The capillary TMP in the cortex was modelled to be 9% above
389 normal but in the white matter it was 33% below normal.⁵¹ It was argued an open BBB would make
390 the cortex over-produce CSF but the white matter would absorb CSF and the balance would result
391 in a normal ICP.⁵¹ Therefore, if this is true, we would expect there to be reversed flow in the

392 aqueduct to accomplish this. Linstrom et al measured the CSF flow through the aqueduct in normal
393 controls using phase contrast MRI and found it to be antegrade (coming out of the ventricles) at
394 0.18 ml/min but the flow was retrograde (going in) in 65% of patients with NPH who improved
395 following shunt.⁵² These patients had 1.49 ml/min entering their ventricles.⁵² Given the grey matter
396 makes up 65% of the brain, this would give a parenchymal interstitial fluid production rate of 0.15
397 m/100g/min, which is between the interstitial fluid production rate for the skin and liver as
398 discussed previously. If the brain were not absorbing this fluid into the deep white matter at the
399 same rate, then the 1.49 ml/min would be added to the 0.33 produced by the choroid plexus and
400 glucose metabolism. Using Davson's equation (1) the resultant CSF_{fr} of 1.82 ml/min, together with
401 a normal R_{out} of 10 mmHg/ml/min and a normal sinus pressure of 7.5 mmHg, would give a resultant
402 ICP of 25.7 mmHg in NPH, which is way above the normal range. Note, we used a normal R_{out} of
403 10 mmHg/ml/min in the moderate AD model and used Davson's equation to calculate a net CSF_{fr} of
404 0.18 mls/min. This compares to Silverberg et al.'s finding of a net CSF_{fr} of 0.2 mls/min in moderate
405 AD,⁵³ suggesting our use of a normal R_{out} in AD is probably correct. The brain in NPH appears to
406 make its deep white matter ischemic to allow the ICP to return to the normal range. In AD, unlike
407 NPH, the maximal reduction in the capillary TMP is in the cortex and not the white matter³³ and so
408 excess CSF production would be moderated at its source. There is a progressive reduction in the
409 ICP in MCI and with AD grade as shown in fig 1 and the net CSF_{fr} we estimated from Davson's
410 equation also reduces with MCI and with AD grade. This suggests that the progressive reduction in
411 the capillary TMP we have estimated could be both correcting the over production of CSF and also
412 reducing the net CSF production as well. Alternatively, the choroid plexus net CSF production may
413 be being progressively down regulated secondary to the dysregulation of its protein synthesis.⁵⁴ It is
414 suggested altered gene expression within the choroid plexus produces down regulation of CSF
415 production in AD.⁵⁵ In MCI, the variable hyper-perfusion of brain regions with an intact BBB may

416 be masking the effect of hypo-perfusion in areas with a deficient BBB in this global CBF study.
417 However, the reduction in ICP in MCI suggests the hypo-perfused areas may be dominating with
418 regards to a reduction in the CSF_{fr}.

419 The possibility that the BBB disruption is being mitigated in the cortex could explain an
420 otherwise difficult problem. The capillaries in AD have pathological changes of coiling and
421 beading, as well as basement membrane disruption indicating BBB disruption.⁵⁶⁻⁵⁸ The ratio of the
422 albumin concentration within the CSF to the serum (Qalb) is thought to represent a measure of BBB
423 breakdown. The cut off for this metric is generally accepted to be 8, with a high number
424 representing increased BBB breakdown.⁵⁹ In AD the Qalb was measured to be 7.8 ± 4.8 in those
425 with the highest quartile of ICP (early disease), 5.0 ± 1.5 in the next, 6.3 ± 2.7 in the next and $12.0 \pm$
426 12.7 in the lowest (severe disease).⁷ Therefore, according to the Qalb ratio, the BBB disruption only
427 becomes a problem in severe AD and not early on (unlike all of the other evidence as presented).
428 However, if the leakage of this protein were being opposed at the site of its production by a
429 reduction in the capillary TMP (opposing the diffusion of the protein by reversing the CSF flow),
430 then this unexpected result could be explained.

431 *Why is the blood brain barrier disrupted in AD?*

432 The vascular hypothesis of AD was first suggested by de la Torre and Mussivand in 1993
433 and was a significant departure from the previous amyloid first paradigm.⁶⁰ One of the current
434 authors in 2004 extended the vascular hypothesis to propose that normal aging and senile dementia
435 may be manifestations of a breakdown in arterial pulsation dampening, with either too large an
436 arterial pulsation to be dampened, too small a compliance in the outflow pathways to allow
437 dampening, or a combination of both.⁶¹ It was suggested that a form of pulse-wave encephalopathy
438 could ensue if this dampening failed.⁶¹ This hypothesis was tested in a pilot study of 12 patients
439 with mild to moderate AD, compared to 12 age matched controls. The mean arterial pressure was

440 the same as the controls but the pulse pressure in AD was 9% higher. Using 2D phase contrast MR
441 flow quantification, the arterial pulse volume within the arterial inflow flow was found to be 13.5%
442 less than controls. Dividing the arterial pulse volume by the arterial pulse pressure suggested the
443 compliance of the arterial tree in AD was reduced by 20% ($p=0.05$).¹² Thus, in AD there is
444 stiffening of the arterial tree which may increase the pulse pressure within the capillary bed due to a
445 reduction in the dampening of this pressure from the reduced arterial compliance.¹² The arterial
446 inflow pulse pressure increases with aging, because the large elastic and muscular arteries become
447 stiffer and the pulse pressure within the vascular system increases.⁶² The cerebral vessels also
448 become stiffer with age.⁶² The increased pulse pressure is correlated with cognitive loss and
449 neurodegeneration.⁶² A mouse model of carotid stiffness showed that blood brain barrier disruption
450 occurred as a direct consequence of an increased pulse pressure.⁶³ This represents the first part of
451 the two-hit hypothesis in AD. According to the two-hit hypothesis, damage to the brain's
452 microcirculation occurs from aging and vascular risk factors such as hypertension, cerebrovascular
453 disease, diabetes and hyperlipidaemia which lead to BBB dysfunction.⁶⁴ This leads to the second hit
454 i.e., increased amyloid β accumulation and impaired clearance.⁶⁴

455 *The cause of the second hit*

456 We have suggested that the initiating event in AD is breakdown of the BBB secondary to an
457 elevated pulse pressure. The BBB disruption would be expected to increase the risk of toxic
458 chemicals passing into the brain as well as the passage of bacteria and viruses. We suggest the brain
459 mitigates this effect by making itself ischemic to reduce the leakage of these toxins. Unfortunately,
460 this strategy is not without consequences. The prolonged ischemia will eventually lead to loss of
461 synapses and whole neurones due to the accumulating ischemic damage.

462 The other problem is the accumulation of amyloid- β precursor protein components within
463 the brain. Low CSF concentrations of amyloid beta ($A\beta$) products in patients with AD correlates

464 with a high brain deposition, suggesting decreased clearance of these toxins.⁶⁵ In early AD, before
465 patients are symptomatic, CSF A β is reduced but there is increased amyloid PET tracer retention.⁶⁶
466 After a variable lag period, neuronal dysfunction and neurodegeneration develop.⁶⁶ Weller noted A β
467 appears to accumulate within the perivascular interstitial fluid drainage pathways of the brain.⁶⁷ The
468 modern understanding of the interstitial drainage pathways comes from the glymphatic hypothesis.
469 It is thought that CSF passes into the arterial perivascular spaces to percolate through the brain
470 parenchyma and exit via the venous perivascular spaces into the subarachnoid space and also the
471 lymphatics within the dura.⁶⁸ Glymphatic fluid flow can be measured using an MRI technique
472 called DTI-ALPS (diffusion tensor imaging along the perivascular space). Using this technique,
473 there was noted to be a reduction in glymphatic function in the preclinical and prodromal stages of
474 AD.⁶⁹ A lower ALPS also predicts amyloid deposition, neurodegeneration and clinical
475 progression.⁶⁹ The entrance of the CSF into the periarterial space is thought to require a volume
476 change within the artery i.e., pulsatile blood flow. As we have noted, the volume change in the
477 artery in AD is reduced due to a lower arterial compliance.¹² Unfortunately, this will be exacerbated
478 by the progressive arterial contraction we hypothesise to occur with AD with disease progression.
479 Contraction of the smooth muscle cells in the arteries increases the wall tension and reduces the
480 vessel compliance regardless of the pressure or diameter of the vessel.⁷⁰ Thus, arterial contraction,
481 in an effort to combat the BBB leakage will decrease the arterial volume pulsation and, therefore,
482 the glymphatic flow leading to accumulation of these toxic proteins within the brain.

483 *Limitations*

484 There are many assumptions inherent in the lumped parameter modelling. Poiseuille's
485 equation requires flow through a thin, rigid, circular tube of a Newtonian fluid, without turbulence.
486 To the degree that these assumptions hold, the findings would be accurate. However, despite its
487 limitations, this equation is commonly used in modelling the vasculature in the literature.

488 Some of the data we required for this model is not available from human studies. In its
489 absence, animal studies were utilised. This is exemplified by the data linking the dilatation of the
490 capillaries to the changes in TMP, which was taken from rodent studies and the normal venous
491 TMP, which was obtained from primate studies. We have no way of knowing if the animal data
492 closely approximates human findings, so this is a limitation. Despite this, the model seems to
493 correctly predict the CBV in both severe AD and following a tap test.

494 **Conclusions**

495 The earliest changes in the patients destined to develop AD are vascular stiffening and
496 increase pulse pressure with disruption of the BBB. The brain appears to react by constricting its
497 arteries to reduce the leakage of interstitial fluid and protein in to the parenchyma. This may work
498 for some time and mitigate the risk of BBB disruption. However, eventually ischemic damage and a
499 reduction in glymphatic flow will result. The later increases amyloid accumulation leading to
500 further damage.

501 **Author contributions**

502 Conceptualisation GAB, ARB. Methodology GAB, ARB. Validation ARB. Writing original
503 draft preparation GAB. Writing- Review and editing GAB ARB. All authors read and approved the
504 final manuscript.

505 **Acknowledgments**

506 The authors have no acknowledgments to report.

507 **Funding statement**

508 The authors received no financial support for the research, authorship, and/or publication of
509 this article.

510 **Declaration of conflicting interest**

511 The authors declared no potential conflicts of interest with respect to the research,
512 authorship, and/or publication of this article.

513 **Availability of data and materials**

514 All data utilised in this study is contained within the article.

515 **References**

- 516 1. Iadecola C. The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health
517 and Disease. *Neuron* 2017; 96: 17-42. 2017/09/29. DOI: 10.1016/j.neuron.2017.07.030.
- 518 2. van de Haar HJ, Burgmans S, Jansen JF, et al. Blood-Brain Barrier Leakage in Patients with Early Alzheimer
519 Disease. *Radiology* 2016; 281: 527-535. 2016/10/19. DOI: 10.1148/radiol.2016152244.
- 520 3. Barisano G, Montagne A, Kisler K, et al. Blood-brain barrier link to human cognitive impairment and
521 Alzheimer's Disease. *Nat Cardiovasc Res* 2022; 1: 108-115. 2022/04/23. DOI: 10.1038/s44161-021-00014-4.
- 522 4. Nation DA, Sweeney MD, Montagne A, et al. Blood-brain barrier breakdown is an early biomarker of human
523 cognitive dysfunction. *Nat Med* 2019; 25: 270-276. 2019/01/16. DOI: 10.1038/s41591-018-0297-y.
- 524 5. Nehra G, Bauer B and Hartz AMS. Blood-brain barrier leakage in Alzheimer's disease: From discovery to
525 clinical relevance. *Pharmacol Ther* 2022; 234: 108119. 2022/02/03. DOI: 10.1016/j.pharmthera.2022.108119.
- 526 6. Michinaga S and Koyama Y. Pathogenesis of brain edema and investigation into anti-edema drugs. *Int J Mol*
527 *Sci* 2015; 16: 9949-9975. 2015/05/06. DOI: 10.3390/ijms16059949.
- 528 7. Yang X, Gan J and Ji Y. Association between cerebrospinal fluid pressure and cognition in patients with
529 Alzheimer's disease and Lewy body dementia. *BMC Neurol* 2024; 24: 35. 2024/01/20. DOI: 10.1186/s12883-023-
530 03502-1.
- 531 8. Savolainen S, Paljarvi L and Vapalahti M. Prevalence of Alzheimer's disease in patients investigated for
532 presumed normal pressure hydrocephalus: a clinical and neuropathological study. *Acta Neurochir (Wien)* 1999; 141:
533 849-853. 1999/10/28. DOI: 10.1007/s007010050386.
- 534 9. Adams RD, Fisher CM, Hakim S, et al. Symptomatic Occult Hydrocephalus with "Normal" Cerebrospinal-
535 Fluid Pressure. A Treatable Syndrome. *N Engl J Med* 1965; 273: 117-126. 1965/07/15. DOI:
536 10.1056/NEJM196507152730301.
- 537 10. Castejon OJ. Submicroscopic pathology of human and experimental hydrocephalic cerebral cortex. *Folia*
538 *Neuropathol* 2010; 48: 159-174. 2010/10/07.
- 539 11. Bateman GA and Bateman AR. A lumped parameter modelling study of cerebral autoregulation in normal
540 pressure hydrocephalus suggests the brain chooses to be ischemic. *Sci Rep* 2024; 14: 24373. 2024/10/18. DOI:
541 10.1038/s41598-024-75214-6.
- 542 12. Bateman GA, Levi CR, Schofield P, et al. Quantitative measurement of cerebral haemodynamics in early
543 vascular dementia and Alzheimer's disease. *J Clin Neurosci* 2006; 13: 563-568. 2006/03/17. DOI:
544 10.1016/j.jocn.2005.04.017.
- 545 13. Leeuwis AE, Benedictus MR, Kuijer JPA, et al. Lower cerebral blood flow is associated with impairment in
546 multiple cognitive domains in Alzheimer's disease. *Alzheimers Dement* 2017; 13: 531-540. 2016/10/30. DOI:
547 10.1016/j.jalz.2016.08.013.
- 548 14. Weijs RWJ, Shkredova DA, Brekelmans ACM, et al. Longitudinal changes in cerebral blood flow and their
549 relation with cognitive decline in patients with dementia: Current knowledge and future directions. *Alzheimers Dement*
550 2023; 19: 532-548. 2022/04/30. DOI: 10.1002/alz.12666.
- 551 15. Davson H, Welch K and Segal MB. *Physiology and Pathophysiology of the Cerebrospinal Fluid*. Churchill
552 Livingstone, 1987.
- 553 16. Zislin V and Rosenfeld M. Impedance Pumping and Resonance in a Multi-Vessel System. *Bioengineering*
554 *(Basel)* 2018; 5 2018/08/12. DOI: 10.3390/bioengineering5030063.
- 555 17. Norsk P, Foldager N, Bonde-Petersen F, et al. Central venous pressure in humans during short periods of
556 weightlessness. *J Appl Physiol (1985)* 1987; 63: 2433-2437. 1987/12/01. DOI: 10.1152/jappl.1987.63.6.2433.

- 557 18. Bateman AR, Bateman GA and Barber T. The relationship between cerebral blood flow and venous sinus
558 pressure: can hyperemia induce idiopathic intracranial hypertension? *Fluids Barriers CNS* 2021; 18: 5. 2021/02/06.
559 DOI: 10.1186/s12987-021-00239-2.
- 560 19. del Zoppo GJ, Sharp FR, Heiss WD, et al. Heterogeneity in the penumbra. *J Cereb Blood Flow Metab* 2011;
561 31: 1836-1851. 2011/07/07. DOI: 10.1038/jcbfm.2011.93.
- 562 20. Ursino M. A mathematical study of human intracranial hydrodynamics. Part 1--The cerebrospinal fluid pulse
563 pressure. *Ann Biomed Eng* 1988; 16: 379-401. 1988/01/01. DOI: 10.1007/BF02364625.
- 564 21. Salmon JH and Timperman AL. Effect of intracranial hypotension on cerebral blood flow. *J Neurol Neurosurg*
565 *Psychiatry* 1971; 34: 687-692. 1971/12/01. DOI: 10.1136/jnnp.34.6.687.
- 566 22. Cirovic S, Walsh C and Fraser WD. Mathematical study of the role of non-linear venous compliance in the
567 cranial volume-pressure test. *Med Biol Eng Comput* 2003; 41: 579-588. 2003/10/24. DOI: 10.1007/BF02345321.
- 568 23. Fleischman D, Berdahl JP, Zaydlarova J, et al. Cerebrospinal fluid pressure decreases with older age. *PLoS*
569 *One* 2012; 7: e52664. 2013/01/10. DOI: 10.1371/journal.pone.0052664.
- 570 24. Benabid AL, De Rougemont J and Barge M. [Cerebral venous pressure, sinus pressure and intracranial
571 pressure]. *Neurochirurgie* 1974; 20: 623-632. 1974/12/01.
- 572 25. Bateman GA and Siddique SH. Cerebrospinal fluid absorption block at the vertex in chronic hydrocephalus:
573 obstructed arachnoid granulations or elevated venous pressure? *Fluids Barriers CNS* 2014; 11: 11. 2014/06/24. DOI:
574 10.1186/2045-8118-11-11.
- 575 26. Johnston IH and Rowan JO. Raised intracranial pressure and cerebral blood flow. 3. Venous outflow tract
576 pressures and vascular resistances in experimental intracranial hypertension. *J Neurol Neurosurg Psychiatry* 1974; 37:
577 392-402. 1974/04/01. DOI: 10.1136/jnnp.37.4.392.
- 578 27. Hua J, Liu P, Kim T, et al. MRI techniques to measure arterial and venous cerebral blood volume. *Neuroimage*
579 2019; 187: 17-31. 2018/02/20. DOI: 10.1016/j.neuroimage.2018.02.027.
- 580 28. Menéndez González M. CNS Compartments: The Anatomy and Physiology of the Cerebrospinal Fluid. In:
581 Menéndez González M (ed) *Liquorphoresis: Cerebrospinal Fluid Filtration to Treat CNS Conditions*. Cham: Springer
582 Nature Switzerland, 2023, pp.1-19.
- 583 29. Ekstedt J. CSF hydrodynamic studies in man. 2 . Normal hydrodynamic variables related to CSF pressure and
584 flow. *J Neurol Neurosurg Psychiatry* 1978; 41: 345-353. 1978/04/01. DOI: 10.1136/jnnp.41.4.345.
- 585 30. Claassen J, Thijssen DHJ, Panerai RB, et al. Regulation of cerebral blood flow in humans: physiology and
586 clinical implications of autoregulation. *Physiol Rev* 2021; 101: 1487-1559. 2021/03/27. DOI:
587 10.1152/physrev.00022.2020.
- 588 31. Duelli R and Kuschinsky W. Changes in brain capillary diameter during hypocapnia and hypercapnia. *J Cereb*
589 *Blood Flow Metab* 1993; 13: 1025-1028. 1993/11/01. DOI: 10.1038/jcbfm.1993.129.
- 590 32. R DES, Ranieri A and Bonavita V. Starling resistors, autoregulation of cerebral perfusion and the pathogenesis
591 of idiopathic intracranial hypertension. *Panminerva Med* 2017; 59: 76-89. 2016/09/07. DOI: 10.23736/S0031-
592 0808.16.03248-1.
- 593 33. Tohgi H, Yonezawa H, Takahashi S, et al. Cerebral blood flow and oxygen metabolism in senile dementia of
594 Alzheimer's type and vascular dementia with deep white matter changes. *Neuroradiology* 1998; 40: 131-137.
595 1998/04/30. DOI: 10.1007/s002340050553.
- 596 34. Zhang H, Wang Y, Lyu D, et al. Cerebral blood flow in mild cognitive impairment and Alzheimer's disease: A
597 systematic review and meta-analysis. *Ageing Res Rev* 2021; 71: 101450. 2021/08/23. DOI: 10.1016/j.arr.2021.101450.
- 598 35. Camargo A, Wang Z and Alzheimer's Disease Neuroimaging I. Hypo- and hyper-perfusion in MCI and AD
599 identified by different ASL MRI sequences. *Brain Imaging Behav* 2023; 17: 306-319. 2023/03/28. DOI:
600 10.1007/s11682-023-00764-8.
- 601 36. Binnewijzend MA, Benedictus MR, Kuijer JP, et al. Cerebral perfusion in the predementia stages of
602 Alzheimer's disease. *Eur Radiol* 2016; 26: 506-514. 2015/06/05. DOI: 10.1007/s00330-015-3834-9.
- 603 37. de Eulate RG, Goni I, Galiano A, et al. Reduced Cerebral Blood Flow in Mild Cognitive Impairment Assessed
604 Using Phase-Contrast MRI. *J Alzheimers Dis* 2017; 58: 585-595. 2017/04/30. DOI: 10.3233/JAD-161222.
- 605 38. Leijenaar JF, van Maurik IS, Kuijer JPA, et al. Lower cerebral blood flow in subjects with Alzheimer's
606 dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic
607 resonance imaging. *Alzheimers Dement (Amst)* 2017; 9: 76-83. 2017/12/14. DOI: 10.1016/j.dadm.2017.10.001.
- 608 39. Roher AE, Debbins JP, Malek-Ahmadi M, et al. Cerebral blood flow in Alzheimer's disease. *Vasc Health Risk*
609 *Manag* 2012; 8: 599-611. 2012/10/31. DOI: 10.2147/VHRM.S34874.
- 610 40. Asllani I, Habeck C, Scarmeas N, et al. Multivariate and univariate analysis of continuous arterial spin labeling
611 perfusion MRI in Alzheimer's disease. *J Cereb Blood Flow Metab* 2008; 28: 725-736. 2007/10/26. DOI:
612 10.1038/sj.jcbfm.9600570.

- 613 41. Nagata K, Kondoh Y, Atchison R, et al. Vascular and metabolic reserve in Alzheimer's disease. *Neurobiol*
614 *Aging* 2000; 21: 301-307. 2000/06/27. DOI: 10.1016/s0197-4580(00)00130-5.
- 615 42. Croteau E, Castellano CA, Fortier M, et al. A cross-sectional comparison of brain glucose and ketone
616 metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease. *Exp Gerontol*
617 2018; 107: 18-26. 2017/07/16. DOI: 10.1016/j.exger.2017.07.004.
- 618 43. Tuniz F, Vescovi MC, Bagatto D, et al. The role of perfusion and diffusion MRI in the assessment of patients
619 affected by probable idiopathic normal pressure hydrocephalus. A cohort-prospective preliminary study. *Fluids*
620 *Barriers CNS* 2017; 14: 24. 2017/09/14. DOI: 10.1186/s12987-017-0072-3.
- 621 44. Mathew NT, Meyer JS, Hartmann A, et al. Abnormal cerebrospinal fluid-blood flow dynamics. Implications in
622 diagnosis, treatment, and prognosis in normal pressure hydrocephalus. *Arch Neurol* 1975; 32: 657-664. 1975/10/01.
623 DOI: 10.1001/archneur.1975.00490520027003.
- 624 45. Meyer JS, Miyakawa Y, Ishihara N, et al. Effect of cerebrospinal fluid removal on cerebral blood flow and
625 metabolism in patients with Alzheimer's disease versus recent stroke. *Stroke* 1977; 8: 44-50. 1977/01/01. DOI:
626 10.1161/01.str.8.1.44.
- 627 46. Mamo HL, Meric PC, Ponsin JC, et al. Cerebral blood flow in normal pressure hydrocephalus. *Stroke* 1987;
628 18: 1074-1080. 1987/11/01. DOI: 10.1161/01.str.18.6.1074.
- 629 47. Cserr HF. Physiology of the choroid plexus. *Physiol Rev* 1971; 51: 273-311. 1971/04/01. DOI:
630 10.1152/physrev.1971.51.2.273.
- 631 48. Bach C and Lewis GP. Lymph flow and lymph protein concentration in the skin and muscle of the rabbit hind
632 limb. *J Physiol* 1973; 235: 477-492. 1973/12/01. DOI: 10.1113/jphysiol.1973.sp010398.
- 633 49. Alexander JS, Ganta VC, Jordan PA, et al. Gastrointestinal lymphatics in health and disease. *Pathophysiology*
634 2010; 17: 315-335. 2009/12/22. DOI: 10.1016/j.pathophys.2009.09.003.
- 635 50. Eide PK and Hansson HA. Blood-brain barrier leakage of blood proteins in idiopathic normal pressure
636 hydrocephalus. *Brain Res* 2020; 1727: 146547. 2019/11/13. DOI: 10.1016/j.brainres.2019.146547.
- 637 51. Bateman GA and Bateman AR. A Lumped Parameter Model Suggests That Infusion Studies Overestimate the
638 Cerebrospinal Fluid Outflow Resistance in Normal Pressure Hydrocephalus. *Brain Sci* 2024; 14: 1242. DOI:
639 10.3390/brainsci14121242.
- 640 52. Lindstrom EK, Ringstad G, Mardal KA, et al. Cerebrospinal fluid volumetric net flow rate and direction in
641 idiopathic normal pressure hydrocephalus. *Neuroimage Clin* 2018; 20: 731-741. 2018/09/22. DOI:
642 10.1016/j.nicl.2018.09.006.
- 643 53. Silverberg GD, Heit G, Huhn S, et al. The cerebrospinal fluid production rate is reduced in dementia of the
644 Alzheimer's type. *Neurology* 2001; 57: 1763-1766. 2001/11/28. DOI: 10.1212/wnl.57.10.1763.
- 645 54. Delvenne A, Vandendriessche C, Gobom J, et al. Involvement of the choroid plexus in Alzheimer's disease
646 pathophysiology: findings from mouse and human proteomic studies. *Fluids Barriers CNS* 2024; 21: 58. 2024/07/18.
647 DOI: 10.1186/s12987-024-00555-3.
- 648 55. Kant S, Stopa EG, Johanson CE, et al. Choroid plexus genes for CSF production and brain homeostasis are
649 altered in Alzheimer's disease. *Fluids Barriers CNS* 2018; 15: 34. 2018/12/14. DOI: 10.1186/s12987-018-0120-7.
- 650 56. Kalaria RN. Cerebral vessels in ageing and Alzheimer's disease. *Pharmacol Ther* 1996; 72: 193-214.
651 1996/01/01. DOI: 10.1016/s0163-7258(96)00116-7.
- 652 57. Higuchi Y, Miyakawa T, Shimoji A, et al. Ultrastructural changes of blood vessels in the cerebral cortex in
653 Alzheimer's disease. *Jpn J Psychiatry Neurol* 1987; 41: 283-290. 1987/06/01. DOI: 10.1111/j.1440-
654 1819.1987.tb00414.x.
- 655 58. Buee L, Hof PR and Delacourte A. Brain microvascular changes in Alzheimer's disease and other dementias.
656 *Ann N Y Acad Sci* 1997; 826: 7-24. 1997/11/05. DOI: 10.1111/j.1749-6632.1997.tb48457.x.
- 657 59. Toniolo S, Di Lorenzo F, Bernardini S, et al. Blood-Brain Barrier Dysfunction and Aβ_{42/40} Ratio Dose-
658 Dependent Modulation with the ApoE Genotype within the ATN Framework. *Int J Mol Sci* 2023; 24 2023/08/12. DOI:
659 10.3390/ijms241512151.
- 660 60. de la Torre JC and Mussivand T. Can disturbed brain microcirculation cause Alzheimer's disease? *Neurol Res*
661 1993; 15: 146-153. 1993/06/01. DOI: 10.1080/01616412.1993.11740127.
- 662 61. Bateman GA. Pulse wave encephalopathy: a spectrum hypothesis incorporating Alzheimer's disease, vascular
663 dementia and normal pressure hydrocephalus. *Med Hypotheses* 2004; 62: 182-187. 2004/02/14. DOI: 10.1016/S0306-
664 9877(03)00330-X.
- 665 62. Reeve EH, Barnes JN, Moir ME, et al. Impact of arterial stiffness on cerebrovascular function: a review of
666 evidence from humans and preclinical models. *Am J Physiol Heart Circ Physiol* 2024; 326: H689-H704. 2024/01/12.
667 DOI: 10.1152/ajpheart.00592.2023.

- 668 63. Muhire G, Iulita MF, Vallerand D, et al. Arterial Stiffness Due to Carotid Calcification Disrupts Cerebral
669 Blood Flow Regulation and Leads to Cognitive Deficits. *J Am Heart Assoc* 2019; 8: e011630. 2019/05/07. DOI:
670 10.1161/JAHA.118.011630.
- 671 64. Wierenga CE, Hays CC and Zlatar ZZ. Cerebral blood flow measured by arterial spin labeling MRI as a
672 preclinical marker of Alzheimer's disease. *J Alzheimers Dis* 2014; 42 Suppl 4: S411-419. 2014/08/28. DOI:
673 10.3233/JAD-141467.
- 674 65. Silverberg GD, Mayo M, Saul T, et al. Alzheimer's disease, normal-pressure hydrocephalus, and senescent
675 changes in CSF circulatory physiology: a hypothesis. *Lancet Neurol* 2003; 2: 506-511. 2003/07/25. DOI:
676 10.1016/s1474-4422(03)00487-3.
- 677 66. Jack CR, Jr., Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy
678 both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. *Brain* 2010; 133: 3336-3348.
679 2010/10/12. DOI: 10.1093/brain/awq277.
- 680 67. Weller RO, Massey A, Kuo YM, et al. Cerebral amyloid angiopathy: accumulation of A beta in interstitial
681 fluid drainage pathways in Alzheimer's disease. *Ann N Y Acad Sci* 2000; 903: 110-117. 2000/05/20. DOI:
682 10.1111/j.1749-6632.2000.tb06356.x.
- 683 68. Nedergaard M. Neuroscience. Garbage truck of the brain. *Science* 2013; 340: 1529-1530. 2013/07/03. DOI:
684 10.1126/science.1240514.
- 685 69. Huang SY, Zhang YR, Guo Y, et al. Glymphatic system dysfunction predicts amyloid deposition,
686 neurodegeneration, and clinical progression in Alzheimer's disease. *Alzheimers Dement* 2024; 20: 3251-3269.
687 2024/03/19. DOI: 10.1002/alz.13789.
- 688 70. Moir ME, Klassen SA, Zamir M, et al. Regulation of cerebrovascular compliance compared with forearm
689 vascular compliance in humans: a pharmacological study. *Am J Physiol Heart Circ Physiol* 2023; 324: H100-H108.
690 2022/12/03. DOI: 10.1152/ajpheart.00377.2022.

691

692 **Statements and Declarations**

693 **Ethical considerations**

694 Not applicable.

695 **Informed Consent Statement**

696 Not applicable.

697 **Consent to participate**

698 Not applicable

699 **Consent for publication**

700 Not applicable